Drug intelligence / Profile preview

GB-3007

Development stage: Preclinical
Lead developer: Shanghai Genbase Biotechnology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GB-3007 is an investigational T cell receptor (TCR) therapy targeting the cancer/testis antigen NY-ESO-1. It is designed as a T lymphocyte replacement therapy and functions as a NY-ESO-1 inhibitor. The drug is being developed primarily for oncology indications, specifically multiple myeloma and synovial sarcoma. The developer and active organization behind this therapy is Shanghai Genbase Biotechnology Co. Ltd. As of the latest available data (March 2025), its highest development phase is preclinical for multiple myeloma and discovery stage for synovial sarcoma[1].

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on GB-3007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-3007.

Explore the full profile